HBSP (USA)
-
Gazprom (A): energéticos y estrategia en la historia de Rusia
Abdelal, Rawi; Tarontsi, Sogomon; Jorov, AlexanderCase HBS-711S28EconomicsLos críticos han acusado a Gazprom, el mayor productor de gas natural del mundo, de las evitando los principios del mercado a favor de las prioridades de política exterior del gobierno ruso, desde el corte gigante de la energía el suministro a Ucrania en enero de 2006. El motivo pretendido para la decisión sin embargo, parece indicar lo contrario: la empresa alegó que no tenía otra opción porque las partes no pudieron llegar a la conclusión de un...Starting at €8.20
-
Building an Integrated Biopharma Company: Crucell (A)
Hamermesh, Richard G.; Van Der Steen, Marianne; Harmeling, Susan S.Case HBS-815085-EEntrepreneurshipBy 2009, Crucell had become the largest biopharma company in the Netherlands and a symbol of national pride. The case traces the evolution of the company from a University spin-off into a fully-integrated company. Crucell's success, particularly in the vaccine space, had begun to attract the attention of much larger pharmaceutical companies. While there was much appeal to working with these companies, these relationships could also challenge Cruc...Starting at €8.20
-
Gazprom (A): Energy and Strategy in Russian History
Abdelal, Rawi; Tarontsi, Sogomon; Jorov, AlexanderCase HBS-709008-EEconomicsCritics have accused Gazprom, the world's largest natural gas producer, of eschewing market principles in favor of the foreign policy priorities of the Russian government, ever since the energy giant cut off the supply to Ukraine in January of 2006. The purported motive for the decision, however, seems to indicate the opposite: the company claimed that it had no other choice because the sides failed to conclude a contract on the terms of future t...Starting at €8.20
-
Building an Integrated Biopharma Company: Crucell (B)
Hamermesh, Richard G.; Van Der Steen, Marianne; Harmeling, Susan S.Case HBS-815086-EEntrepreneurshipThe Crucell (B) case updates events at Crucell since 2009. In September, 2009, Johnson & Johnson acquired 18% of Crucell for $400 million. This investment was part of a business development deal. Subsequently, in 2012, Johnson & Johnson acquired Crucell for $2.8 billion.Starting at €5.74